A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors

Mutant serine/threonine protein kinase B-Raf (BRAF) protein is expressed in over half of all melanoma tumors. Although BRAF inhibitors (BRAFi) elicit rapid anti-tumor responses in the majority of patients with mutant BRAF melanoma, the tumors inevitably relapse after a short time. We hypothesized th...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Molly C., Minton, Allyson, Phanstiel, Otto, Gilmour, Susan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872160/
https://www.ncbi.nlm.nih.gov/pubmed/29304009
http://dx.doi.org/10.3390/medsci6010003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872160/
https://www.ncbi.nlm.nih.gov/pubmed/29304009
http://dx.doi.org/10.3390/medsci6010003

Ejemplares similares